Home › Funds › EQT Fund Management S.a r.l. › AGMB

EQT Fund Management S.a r.l. position in AGMB

Agomab Therapeutics NV · Health Care

EQT Fund Management S.a r.l. reported holding 5,141,992 shares of AGMB (Agomab Therapeutics NV) in its Q3 2026 13F filing — a position valued at US$57.1M, representing 6.02% of its reported portfolio and ranking #4 among its reported holdings. EQT Fund Management S.a r.l. has disclosed AGMB holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

Latest position (Q3 2026)5.14M sh
Reported value held$57.08M
Portfolio Weight6.02%
First reportedQ1 2026
Last changeHold
Updated2026-11-12

Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR

How EQT Fund Management S.a r.l.'s AGMB position evolved

EQT Fund Management S.a r.l. first disclosed a stake in AGMB in Q1 2026 at 5,141,992 shares (US$53.9M). The position peaked in Q2 2026 at 5,141,992 shares, worth US$66.7M. Across 3 filings, EQT Fund Management S.a r.l. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 5,141,992 shares valued at US$57.1M.

Quarter by quarter

QuarterSharesValueChange
Q1 2026 5.14M $53.94M New
Q2 2026 5.14M $66.74M Hold
Q3 2026 5.14M $57.08M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AGMB and 13F data

AGMB (Agomab Therapeutics NV) is a Health Care company. 34 other funds we track also report a position in AGMB — the largest reported positions include Redmile Group, LLC (US$35.5M), Cormorant Asset Management, LP (US$32.0M), Sanofi (US$30.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AGMB

All AGMB fund holders →

FAQ

How long has EQT Fund Management S.a r.l. held AGMB?

EQT Fund Management S.a r.l. has disclosed AGMB holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

What is EQT Fund Management S.a r.l.'s current position in AGMB?

As of Q3 2026, EQT Fund Management S.a r.l. holds 5.14M shares of AGMB (Agomab Therapeutics NV), valued at $57.08M, representing 6.02% of its reported portfolio and ranking #4.

Has EQT Fund Management S.a r.l. been buying or selling AGMB?

In the latest 13F filing (Q3 2026), EQT Fund Management S.a r.l. held unchanged its position in AGMB. The position peaked in Q2 2026 at 5.14M shares.

Which other funds hold AGMB?

Other major institutional holders of AGMB include Redmile Group, LLC, Cormorant Asset Management, LP, Sanofi, among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.